يعرض 1 - 10 نتائج من 63 نتيجة بحث عن '"hdl particles"', وقت الاستعلام: 0.86s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المصدر: Kunutsor , S K , Bhattacharjee , A , Connelly , M A , Bakker , S J L & Dullaart , R P F 2024 , ' Alcohol Consumption, High-Density Lipoprotein Particles and Subspecies, and Risk of Cardiovascular Disease : Findings from the PREVEND Prospective Study ' , International Journal of Molecular Sciences , vol. 25 , no. 4 , 2290 . https://doi.org/10.3390/ijms25042290Test

    وصف الملف: application/pdf

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المصدر: Post , A , Garcia , E , Gruppen , E G , Kremer , D , Connelly , M A , Bakker , S J L & Dullaart , R P F 2022 , ' Higher Free Triiodothyronine Is Associated With Higher HDL Particle Concentration and Smaller HDL Particle Size ' , Journal of Clinical Endocrinology & Metabolism , vol. 107 , no. 5 , pp. e1807–e1815 . https://doi.org/10.1210/clinem/dgac044Test

    وصف الملف: application/pdf

  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية

    المساهمون: Medicum, Institute for Molecular Medicine Finland, Complex Disease Genetics, University of Helsinki

    وصف الملف: application/pdf

    العلاقة: Rotterdam Study: The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; The Netherlands Organisation for Scientific Research; The Netherlands Organisation for Health Research and Development; the Research Institute for Diseases in the Elderly; The Netherlands Genomics Initiative; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam. Metabolomics measurements were funded by Biobanking and Biomolecular Resources Research Infrastructure-NL (184.021.007) and the JNPD under the project PERADES (grant 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease Using Multiple Powerful Cohorts, Focused Epigenetics and Stem Cell metabolomics). This work has been performed as part of the CoSTREAM project (costream.eu), Memorabel program (project number 733050814) and has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 667375. This work has been performed as part of the CardioVasculair Onderzoek Nederland (CVON 2012-03). Whitehall II: The Whitehall II study is supported by the Medical Research Council (MR/R024227/1) and the British Heart Foundation (32334). M. Kivimaki is supported by the Medical Research Council (S011676/1), NordForsk, the Academy of Finland (311492), and Helsinki Institute of Life Science. The authors thank all of the participating civil service departments and their welfare, personnel, and establishment officers; the British Occupational Health and Safety Agency; the British Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and all members of theWhitehall II study team. TheWhitehall II Study team comprises research scientists, statisticians, study coordinators, nurses, data managers, administrative assistants, and data entry staff, who make the study possible. FINRISK97 and DILGOM: The FINRISK studies have received financial support from the National Institute for Health and Welfare and the Academy of Finland (139635) and the Finnish Foundation for Cardiovascular Research (to V.S). Additional funding has been obtained from the Academy of Finland (grants 297338, 307247), the Novo Nordisk Foundation (NNF17OC0026062), the Sigrid Juselius Foundation, and University of Oulu Graduate School. M. A.-K. is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia (APP1158958). He also works in a unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_12013/1). The Baker Institute is supported in part by the Victorian Government's Operational Infrastructure Support Program. J.K. was supported through funds from the Academy of Finland (grants 297338 and 307247) and Novo Nordisk Fonden (grant NNF17OC0026062). PROSPER: This work (NMR) was supported by the European Federation of Pharmaceutical Industries Associations, Innovative Medicines Initiative Joint Undertaking, European Medical Information Framework grant 115372, and the European Commission under theHealthCooperationWork Programme of the 7th Framework Programme (grant 305507) "Heart `omics' in AGEing" (HOMAGE). The PROSPER study was supported by an investigator-initiated grant obtained from Bristol-Myers Squibb. Dr. J.W. Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant 2001 D 032). EGCUT: This work was supported by Estonian Research Council (IUT20-60, PUT1660 to T.E.; Vojinovic , D , Kalaoja , M , Trompet , S , Fischer , K , Shipley , M J , Li , S , Havulinna , A S , Perola , M , Salomaa , V , Yang , Q , Sattar , N , Jousilahti , P , Amin , N , Satizabal , C L , Taba , N , Sabayan , B , Vasan , R S , Ikram , M A , Stott , D J , Ala-Korpela , M , Jukema , J W , Seshadri , S , Kettunen , J , Kivimaki , M , Esko , T & van Duijn , C M 2021 , ' Association of Circulating Metabolites in Plasma or Serum and Risk of Stroke Meta-analysis From 7 Prospective Cohorts ' , Neurology , vol. 96 , no. 8 , pp. E1110-E1123 . https://doi.org/10.1212/WNL.0000000000011236Test; http://hdl.handle.net/10138/332953; ed36cbd4-d020-462a-b558-75e0103e319a; 000656635300017

    الإتاحة: http://hdl.handle.net/10138/332953

  10. 10
    دورية أكاديمية